Moderna Inc. (MRNA) shares closed at USD 198.88 on September 25, 2026, representing a gain of 2.08 percent from the prior session. The stock price reflects ongoing investor interest in the biotechnology firm's pipeline developments and recent corporate announcements regarding its investigational therapies. Moderna announced that three abstracts concerning intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The congress is scheduled to take place from October 23 through October 27. The core of the presentation program includes Phase 3 data from the INTerpath-001 study, which evaluates intismeran autogene plus pembrolizumab versus pembrolizumab alone in patients with resected stage IIB-IV melanoma. Additionally, the company will present Phase I data for a pancreatic cancer study and Phase 3 results for high-risk stage I non-small cell lung cancer. Moderna plans to host an investor webcast on October 24 at 7:00 p.m. CEST (1:00 p.m. EDT) to discuss these findings, with a replay available for at least 30 days. ACCESS Newswire identified Moderna and Merck as joint developers of intismeran autogene.